Additional genetic analyses are needed in large prospective cohorts of adult cancer patients treated with anthracyclines and followed for extended periods of time to further investigate the role of CBR3 V244M across patients of different ages, cancer types, and treatment regimes. Here, CBR3 is linked to cancer.